GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Spero Therapeutics Inc (NAS:SPRO) » Definitions » 14-Day RSI

Spero Therapeutics (Spero Therapeutics) 14-Day RSI : 34.58 (As of Apr. 26, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Spero Therapeutics 14-Day RSI?

The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.

As of today (2024-04-26), Spero Therapeutics's 14-Day RSI is 34.58.

The industry rank for Spero Therapeutics's 14-Day RSI or its related term are showing as below:

SPRO's 14-Day RSI is ranked better than
78.98% of 1575 companies
in the Biotechnology industry
Industry Median: 43.5 vs SPRO: 34.58

Competitive Comparison of Spero Therapeutics's 14-Day RSI

For the Biotechnology subindustry, Spero Therapeutics's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Spero Therapeutics's 14-Day RSI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Spero Therapeutics's 14-Day RSI distribution charts can be found below:

* The bar in red indicates where Spero Therapeutics's 14-Day RSI falls into.



Spero Therapeutics  (NAS:SPRO) 14-Day RSI Calculation

The formula for calculating RSI is:

RSI=100[ 100 / ( 1 + Average Gain / Average Loss )]

* Note that the formula uses a positive value for the average loss.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Spero Therapeutics  (NAS:SPRO) 14-Day RSI Explanation

The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.

Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.

RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.


Spero Therapeutics 14-Day RSI Related Terms

Thank you for viewing the detailed overview of Spero Therapeutics's 14-Day RSI provided by GuruFocus.com. Please click on the following links to see related term pages.


Spero Therapeutics (Spero Therapeutics) Business Description

Traded in Other Exchanges
Address
675 Massachusetts Avenue, 14th Floor, Cambridge, MA, USA, 02139
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
Executives
Kamal Hamed officer: Chief Medical Officer 675 MASSACHUSETTS AVENUE, 14TH FLOOR, CAMBRIDGE MA 02139
Sath Shukla officer: Chief Financial Officer C/O ZIOPHARM ONCOLOGY, INC., ONE FIRST AVENUE, PARRIS BUILDING #34, BOSTON MA 02129
Timothy Keutzer officer: Chief Development Officer C/O SPERO THERAPEUTICS, INC., 675 MASSACHUSETTS AVENUE, 14TH FLOOR, CAMBRIDGE MA 02139
Ankit Mahadevia director, officer: See Remarks C/O SPERO THERAPEUTICS, INC., 675 MASSACHUSETTS AVE., 14TH FLOOR, CAMBRIDGE MA 02139
Tamara L Joseph officer: Chief Legal Officer 32 GARRISON STREET, APT 50-103, BOSTON MA 02116
Aquilo Capital Management, Llc 10 percent owner ONE LETTERMAN DRIVE, SUITE D4900, BUILDING D, SAN FRANCISCO CA 94129
Kathleen Tregoning director C/O CEREVEL THERAPEUTICS HOLDINGS, INC., 131 DARTMOUTH STREET SUITE 502, BOSTON MA 02116
Cristina Larkin officer: Chief Operating Officer C/O SPERO THERAPEUTICS, INC., 675 MASSACHUSETTS AVENUE, 14TH FLOOR, CAMBRIDGE MA 02139
Aquilo Capital, L.p. 10 percent owner ONE LETTERMAN DRIVE, SUITE D4900, BUILDING D, THE PRESIDIO, SAN FRANCISCO CA 94129
Scott Thomas Jackson director 303B COLLEGE ROAD EAST, PRINCETON NJ 08540
Stephen J. Dipalma officer: Interim CFO C/O SPERO THERAPEUTICS, INC., 675 MASSACHUSETTS AVENUE, 14TH FLOOR, CAMBRIDGE MA 02139
Cynthia Smith director 508 WRANGLER DRIVE, SUITE 100, COPPELL TX 75019
Pottage John C Jr director ACHILLION PHARMACEUTICALS, 300 GEORGE STREET, NEW HAVEN CT 06511
Plc Glaxosmithkline 10 percent owner 980 GREAT WEST ROAD, BRENTFORD MIDDLESEX X0 TW8 9GS
Joel Sendek officer: Chief Financial Officer C/O SPERO THERAPEUTICS, INC., 675 MASSACHUSETTS AVENUE, 14TH FLOOR, CAMBRIDGE MA 02139